Creative Biolabs is fully competent and dedicated to engineering leukemia cells - turning cancer cells against themselves. Enriched experience associated with state-of-the-art facilities, our scientists have developed several efficient Strategies for engineering cancer cells for self-destruction.

Introduction of Leukemia

As a cancer of the blood, leukemia begins when the bone marrow starts to rapidly produce abnormal white blood cells called leukemia cells. They may crowd out normal white blood cells, red blood cells, and platelets, making it hard for the normal cells to work. There are four main types of leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. Chronic and acute leukemias are completely different diseases, and they progress at different speeds.

The way they're treated can be very different. Acute leukemia is an emergency and we need to start therapy right away. The urgency is to manage any life-threatening complications. However, over the last few years, several drugs that focus on destroying cells that have specific mutations have been approved for acute leukemia. As we know, chemotherapies are not suitable for all patients and targeted approaches may help. Therefore, if a patient with acute leukemia does not have a life-threatening complication, a few days are needed to get more information about the disease that can help identify the best treatments. Chronic leukemias can be controlled or treated in much the same way as other chronic disorders. Nevertheless, side effects persist, and novel therapeutic agents are urgently needed for this disease.

Fig.1 Main targeted therapies in acute myeloid leukemia and their downstream pathways. (Megías-Vericat, et al. 2020)

Leukemia Cell Engineering Service at Creative Biolabs

Creative Biolabs combines deep, industry-leading expertise with innovative platforms to inspire the lymphangiogenic potentiation of immunotherapy to turn cancer cells against themselves. A comprehensive range of Cancer Cells is available to be engineered, including but not limited to BV173, Kasumi-1Jurkat, and HL-60.

Our scientists are proficient in multiple Genetic Methods for cell line engineering, including Retrovirus, Lentivirus, cell line engineering by adenovirus, cell line engineering by Adeno-associated Virus , and CRISPR-based Methods. Our strategies for engineering cancer cells for self-destruction, include but are not limited to the following. What's more, Immune Reactivity and Toxicity are needed to assess the effect of self-destruction cancer cells.

• Engineering Cancer Cells with Cytokine Overexpression for Stronger T Cell Activation
• Engineering Cancer Cells with Target-specific Aptamer for Cancer Immunotherapy
• Engineering Cancer Cells With Aptamer-siRNA for Enhanced Antitumor T Cell Immunity
• Engineering Cancer Cells with Synthetic Immunomodulatory Gene Circuits for Cancer Immunotherapy
• Engineering Cancer Cells with Targeted siRNA for Cancer Immunotherapy

For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Megías-Vericat, J.E.; et al. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. Expert Review of Hematology. 2020, 13(10): 1057-65.

For Research Use Only | Not For Clinical Use